Clinical Trial Update: HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial in HPV 16/18-positive recurrent or metastatic head and neck squamous cell carcinoma evaluating a triple therapy of GX-188E DNA vaccine,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• GX-188E DNA Vaccination
• GX-I7
• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: Yonsei University | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING